Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;12(9):1002.
doi: 10.3390/vaccines12091002.

Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review

Chung-I Rai  1 , Tsu-Hsiang Kuo  2   3 , Yuan-Chuan Chen  4   5   6
Affiliations
Review

Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review

Chung-I Rai et al. Vaccines (Basel). .

Abstract

Traditional vaccines can be classified into inactivated vaccines, live attenuated vaccines, and subunit vaccines given orally or via intramuscular (IM) injection or subcutaneous (SC) injection for the prevention of infectious diseases. Recently, recombinant protein vaccines, DNA vaccines, mRNA vaccines, and multiple/alternative administering route vaccines (e.g., microneedle or inhalation) have been developed to make vaccines more secure, effective, tolerable, and universal for the public. In addition to preventing infectious diseases, novel vaccines have currently been developed or are being developed to prevent or cure noninfectious diseases, including cancer. These vaccine platforms have been developed using various biotechnologies such as viral vectors, nanoparticles, mRNA, recombination DNA, subunit, novel adjuvants, and other vaccine delivery systems. In this review, we will explore the development of novel vaccines applying biotechnologies, such as vaccines based on novel administration routes, vaccines based on novel vectors, including viruses and nanoparticles, vaccines applied for cancer prevention, and therapeutic vaccines.

Keywords: adjuvant; biotechnology; delivery system; mRNA; nanoparticle; recombination DNA; therapeutics; vaccine; vector.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interests.

Figures

Figure 1
Figure 1
Comparison of intramuscular (IM) injection, subcutaneous (SC) injection, and microneedle patch.
Figure 2
Figure 2
Building a bridge between traditional vaccines and novel vaccines based on biotechnologies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wang S.-C., Rai C.-I., Chen Y.-C. Challenges and Recent Advancements in COVID-19 Vaccines. Microorganisms. 2023;11:787. doi: 10.3390/microorganisms11030787. - DOI - PMC - PubMed
    1. Rad Z.F., Prewett P.D., Davies G.J. An overview of microneedle applications, materials, and fabrication methods. Beilstein J. Nanotechnol. 2021;12:1034–1046. doi: 10.3762/bjnano.12.77. - DOI - PMC - PubMed
    1. Nguyen H.X., Nguyen C.N. Microneedle-Mediated Transdermal Delivery of Biopharmaceuticals. Pharmaceutics. 2023;15:277. doi: 10.3390/pharmaceutics15010277. - DOI - PMC - PubMed
    1. Li Y., Wang J., Jin Z., Wan W., Bai X., Hu C., Li Y., Xin W., Kang L., Yang H., et al. Microneedle-based percutaneous immunity: A review. Sheng Wu Gong Cheng Xue Bao = Chin. J. Biotechnol. 2022;38:3301–3315. doi: 10.13345/j.cjb.220142. - DOI - PubMed
    1. Mansoor I., Mohammed K.H.A., El-Fattah M.A.A., Abdo M.H., Rashad E., Eassa H.A., Saleh A., Amin O.M., Nounou M.I., Ghoneim O. Microneedle-Based Vaccine Delivery: Review of an Emerging Technology. AAPS Pharmscitech. 2022;23:103. doi: 10.1208/s12249-022-02250-8. - DOI - PMC - PubMed

LinkOut - more resources